Calcium antagonists in migraine and vertigo. Possible mechanisms of action and review of clinical trials

Abstract

Three primary mechanisms have been suggested as an explanation of migraine; a neuronal event, a vascular event and a mechanism focussing on the trigeminal nerve and its supply to intra- and extracranial blood vessels. None of these theories has been adequately proven yet. A neuronal point of impact, rather than a vascular one, seems to be responsible for migraine prophylaxis with calcium antagonists. Primarily vasoactive substances such as nimodipine are not or only marginally effective, whereas flunarizine with a limited vascular activity is effective. Data on other calcium antagonists are insufficient to conclude on a migraine-prophylactic activity. The only calcium antagonist that has been extensively tested for vertigo is flunarizine. In placebo-controlled trials, the drug showed to be effective in labyrinthine vertigo. The mechanism behind this effect is unclear.

Original languageEnglish
JournalEuropean Neurology
Volume30 Suppl 2
Pages (from-to)31-4; discussion 39-41
ISSN0014-3022
DOIs
Publication statusPublished - 1990
Externally publishedYes

Keywords

  • Calcium/physiology
  • Calcium Channel Blockers/therapeutic use
  • Flunarizine/therapeutic use
  • Humans
  • Migraine Disorders/drug therapy
  • Vertigo/drug therapy

Fingerprint

Dive into the research topics of 'Calcium antagonists in migraine and vertigo. Possible mechanisms of action and review of clinical trials'. Together they form a unique fingerprint.

Cite this